CRF1R Inhibitors
1 drugsAbout CRF1R
Corticotropin-releasing factor receptor 1 (CRF1R) is a GPCR mediating the body's stress response via the hypothalamic-pituitary-adrenal (HPA) axis. Activated by corticotropin-releasing factor (CRF), it triggers hormonal and neuronal events. Dysregulation of the HPA axis implicates CRF1R in various conditions.
CRF1R is a compelling drug target due to its role in stress-related disorders. Currently, there is no genetic evidence available linking CRF1R to specific diseases. Further research is needed to explore the therapeutic potential of CRF1R modulation.
CRF1R is targeted by one FDA-approved drug, CRENESSITY (Neurocrine Biosciences), a small molecule. CRENESSITY has one indication in the 'other' therapeutic area. Further investigation into the mechanisms and downstream effects of CRF1R modulation is warranted to fully realize its therapeutic potential.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Healthy with only 1 trials.
Top CRF1R Drugs
The competitive landscape is dominated by Neurocrine Biosciences, the sole company with an approved CRF1R drug.
High market concentration suggests significant entry barriers; consider strategic partnerships or niche indications to gain market access.
CRF1R Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CRF1R, using small molecule modality.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing small molecule approaches.
CRF1R Clinical Trials 5 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 3 | 1 | 0 | 2 | 100% |
| Phase 3 | 2 | 0 | 0 | 2 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CRF1R Drug Approval Timeline (2024 - 2024)
The first and most recent drug approval for CRF1R was CRENESSITY in 2024.
Recent approval indicates renewed interest in CRF1R; monitor clinical trials and emerging data to assess future opportunities.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (6 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 9 clinical trials targeting CRF1R.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities